Verde Capital Management Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Verde Capital Management purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 2,730 shares of the medical research company’s stock, valued at approximately $202,000.

Several other hedge funds and other institutional investors also recently modified their holdings of EW. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter worth about $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences during the third quarter worth about $40,000. Finally, JFS Wealth Advisors LLC boosted its position in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,000 shares of company stock worth $2,195,180. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.1 %

Shares of NYSE EW opened at $68.95 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $40.66 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 3.59 and a beta of 1.11. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm’s 50-day simple moving average is $72.25 and its 200 day simple moving average is $70.86.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.59 EPS. On average, research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on EW shares. Piper Sandler reduced their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup increased their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Stifel Nicolaus increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Evercore ISI reduced their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.